DEERFIELD, Ill., June 07, 2021 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, and Inteneural Networks Inc., a developer of innovative artificial intelligence (AI) based applications focused on fully autonomous analytics of central nervous system imaging, today announced that they have entered into a strategic collaboration agreement. Under the agreement, Surgalign will gain access to Inteneural’s proprietary technology for evaluation of future integration within the Surgalign digital surgery portfolio.
Inteneural is the developer and owner of proprietary intellectual property that allows computers to autonomously segment and identify neural structures in medical images and rapidly deliver reference information using machine learning alogrithims. These algorithms have potential for future applications in cranial and neurosurgery for referencing of tumor, aneurysm, stroke, and neurovascular structures using existing magnetic resonance imaging and computed tomography technology.
“While our initial focus is the application of digital surgery in spine procedures, we have a much more expansive vision for what we believe is possible with emerging technologies. New developments in the application of AI in neurosurgery and medical imaging make it an attractive space to further expand. Inteneural has developed machine learning-based analytics and fully autonomous brain anatomy segmentation capabilities that would be incredibly powerful when combined with neurosurgery,” said Terry Rich, Surgalign Chief Executive Officer. “The agreement between Surgalign and Inteneural sets the foundation for potentially enhanced research and development efficiencies, expansion of the addressable markets, and acceleration of the technological progress in the digital surgery space generally.”
“It’s important to note that this collaboration builds on the overwhelmingly positive feedback we have been receiving recently from spine surgeons, many of whom also specialize in neurosurgery, during demonstrations of the HolosurgicalTM platform,” Mr. Rich added.
The agreement provides for a period during which Surgalign will evaluate the Inteneural technology on an exclusive basis, and work with Inteneural to determine the feasibility of a more comprehensive collaboration.
About Inteneural Networks Inc.
Inteneural Networks Inc. is a Chicago-based medical high-tech company, specializing in AI and Big Data Learning analysis of brain imaging. It was founded in 2017 by experienced scientists and high-tech investors: A pioneer in data mining and big data learning – Professor Paul Lewicki PhD and a surgeon who specializes in high-tech imaging databases and surgical applications – Dr. Kris Siemionow MD, PhD. Lewicki and Siemionow are the founders of the Holosurgical platform.
About Surgalign Holdings, Inc.
Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital surgery and is building out its digital surgery platform to drive transformation across the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company is building technologies surgeons will look to for what is truly possible for their patients. Surgalign is focused on bringing surgeons solutions that predictably deliver superior clinical and economic outcomes.
Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. Surgalign, a member of AdvaMed, is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Marquette, MI, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn and Twitter.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither historical facts or assurances of future performance, but are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “potential” and variations of such words and similar references to future periods are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting Surgalign’s website at www.surgalign.com or the SEC’s website at www.sec.gov.
Investor and Media Contact
+1 224 303 4651